Within Biotechnology & Pharmaceuticals industry 10x Capital Venture Acquisition Corp Iii booked the highest Quick Ratio than 10x Capital Venture Acquisition Iii in the third quarter 2023. While total ranking remained the same in the Q3 2023 compared to the second quarter 2023 at no. .

Explain Quick Ratio?
How much Cash & cash equivalents VCXBU�s has?
What are VCXBU�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

VCXBU Quick Ratio	(Sep 30 2023) Q3	(Jun 30 2023) Q2	(Mar 31 2023) Q1	(Dec 31 2022) Q4	(Sep 30 2022) Q3
Y / Y Current Liabilities Change	1347.08 %	867.72 %	729.81 %	45817.82 %	-
Y / Y Cash & cash equivalent Change	-	299.78 %	-96.23 %	-	-
Quick Ratio MRQ	-	0.47	0.01	0	0.33
VCXBU's Total Ranking	#	#	#	#	#
Seq. Current Liabilities Change	33.02 %	43.72 %	-98.93 %	70448.42 %	-11.05 %
Seq. Cash & cash equivalent Change	-	7640.84 %	-62.19 %	-47.52 %	-73.97 %

Quick Ratio third quarter 2023 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	#
Healthcare Sector	#
Overall Market	#

Quick Ratio Statistics
High	Average	Low
0	0	0

Financial Statements
10x Capital Venture Acquisition Iii's Current Liabilities	$ 6 Millions	Visit VCXBU's Balance sheet
10x Capital Venture Acquisition Iii's Cash & cash equivalent	$ 0 Millions	Visit VCXBU's Balance sheet
Source of VCXBU's Sales		Visit VCXBU's Sales by Geography

Cumulative 10x Capital Venture Acquisition Iii's Quick Ratio

VCXBU's Quick Ratio for the trailling 12 Months

VCXBU Quick Ratio	(Sep 30 2023) 12 Months	(Jun 30 2023) 12 Months	(Mar 31 2023) 12 Months	(Dec 31 2022) 12 Months	(Sep 30 2022) 12 Months
Y / Y Current Liabilities TTM Growth	16047.99 %	20190.75 %	29108.12 %	46015.44 %	-
Y / Y Cash & cash equivalent TTM Growth	59.24 %	87.73 %	5.85 %	-	-
Quick Ratio TTM	0.01	0.01	0	0.01	0.74
Total Ranking TTM	# 4093	# 4091	# 4523	# 4778	# 0
Seq. Current Liabilities TTM Growth	1.86 %	1.36 %	0.94 %	15394.5 %	27.99 %
Seq. Cash & cash equivalent TTM Growth	-5.85 %	206.96 %	-47.62 %	5.2 %	10.99 %

Quick ratio ranking by company, industry and sector >> Back to VCXBU Financial Strength Comparisons >> Go to Compare VCXBU Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the growth in Current Liabilities in the Q3 2023 to $5.52 millions, cumulative Quick Ratio remained unchanged at 0.01 below the 10x Capital Venture Acquisition Corp Iii average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 180 other companies have achieved higher Quick Ratio than 10x Capital Venture Acquisition Iii. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 4091 to 4093.

Explain Quick Ratio?
How much Cash & cash equivalents VCXBU�s has?
What are VCXBU�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 181
Healthcare Sector	# 1092
Within the Market	# 4093

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.01	0.01	0
(Jun 30 2023)		(Mar 31 2023)

Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry

Quick Ratio

Sep 30 2023 MRQ Cash & cash equivalent

Sep 30 2023 MRQ Current Liabilities

Date modified: 2026-06-22T16:30:32+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.